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We read with interest the comments
addressed by Wurtz and coworkers on
our article, ‘‘Tracheal regeneration:
Evidence of bone marrow stem cell in-
volvement.’’1 We greatly appreciate
their congratulations for having pro-
vided a ‘‘convincing demonstration of
bonemarrow–derived stem cell migra-
tion to thegrafted area after tracheal re-
placement with an aortic allograft in
a New Zealand rabbit model.’’ More
generally, we thank them for their
strong support to our pioneering exper-
imental works,2-5 which led to the first
human applications.6,7 Nevertheless,
we would like to discuss some key
points arising from their letter.
In our rabbit model, we observed
a radically different evolution of the
aortic graft. To answer precisely their
comments, neither necrosis nor over-
distention of the thoracic aorta by the
endoprosthesis occurred in our exper-
iments. A stent of 5 mm in diameter1418 The Journal of Thoracic andwas inserted with moderate distention
of the aorta so that the elastic tissue
would not collapse. As shown in Fig-
ure 1 of the original article, stent and
aortic dimensions matched well with
the cervical tracheal diameter after
graft interposition. Moreover, as
underlined by our article, stent migra-
tion was one of the main complica-
tions, proving that the stenting has
not been forcefully made. Perhaps
age and weight of the rabbits in Wurtz
and coworkers’ experimentations
were not properly chosen? We are
also surprised by the polyethylene
tube they reported using in their un-
published studies. In our sheep and hu-
man work, we paid great attention to
base our studies on a tracheal prosthe-
sis that had already been evaluated in
clinical applications, and we decided
to use a flexible pediatric tracheal sili-
cone stent (Tracheobronxane Dumon;
Novatech, La Ciotat, France).
Finally, did Wurtz and coworkers
observe such necrosis both with and
without stenting in their model? The
real difference that we want to under-
line is the allotransplantation site of
the aorta. Also, a muscle flap could
be a better option than a fascial flap
to promote revascularization. This
has been clearly demonstrated in our
experimental and clinical work on air-
way transplantation with aortic
allografts.7,8
We completely agree with Wurtz
and coworkers that ‘‘the presence of
bone marrow mesenchymal stem cells
in the grafted area could result in their
capacity for nonspecific migration and
homing toward different kinds of dam-
aged or injured tissues.’’ As they have
noted, we constructed our experimen-
tations on the basis of mesenchymal
stem cell circulating theory, hypothe-
sizing that injured rabbits would use
circulating mesenchymal stem cells
to avoid bone marrow mobilization.9
It is well known that unspecific
mesenchymal stem cells migrate to in-
flammatory sites attracted by the liber-
ation of chemokines on the place of
injury. The real challenge is to findCardiovascular Surgery c May 2013the other triggers orienting these cells
to secondly differentiate to obtain tra-
cheal regeneration.
We disagree with Wurtz and co-
workers, however, who would com-
pare these uncompleted results on
the rabbit model with the first human
applications, in which cartilage regen-
eration seems to be delayed. The
structure of the human aorta is histo-
logically closer to the aorta of the min-
ipig than to the aorta of the rabbit.
There is still hope to get similar results
to those observed in these experimen-
tations with cartilage regeneration.
We are still working on multiple hy-
potheses to explain the delayed regen-
eration of human cartilage, such as
patient age (older meaning no circu-
lating growth factor), sex influence
(more often men than women), tu-
moral pathology, previous impairing
treatments (chemotherapy), and so on.
To conclude, the myth turned into
reality with the first demonstration of
tracheal regeneration in animal studies
at the beginning of our experience.2-4
Today, the main issue is to obtain
the same regenerative processes in
human beings. A prospective study
(TRACHEOBRONC-ART trial) is in
progress at our center to confirm not
only the feasibility of airway
transplantation with cryopreserved
aortic allograft but also the
possibility of airway regeneration in
human beings.
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